2026 Q2 - tulosraportti
84 päivää sitten
‧32 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 100 | ||
| 4 859 | ||
| 2 000 | ||
| 6 141 | ||
| 922 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. | 7 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·2 t sittenBIOPORTO (Q3) I 2026 regner Bioporto med at omsætte for 38-48 mio. kr. Det justerede driftsresultat før af- og nedskrivninger (EBITDA) ventes at udgøre et tab på 58-68 mio. kr.
Dear 3D Why are you posting this? You aren't even posting it with a degree of understanding of what you are posting! BioPorto (Q3)... etc. When there is even something called Q3, it is because you have copied from the financial calendar.. As you have made yourself satisfied with what was published, it COULD be read as a kind of description OF Q3! However, it is not, and you have clipped it out of a calendar where Q3 is announced (Not WHAT is in the report, but THAT the report is coming on this and that day! So you are missing a date!!!! Besides, what you are posting is just 100% uninformative. I understand so little about you and am fed up to the back teeth with your unqualified messages! I think you should consider how insistent you are in your way of shoving yourself down over "a reality". Mvh. Bagerbrød- ·4 t sitten · MuokattuMarwah Medicine (digital information platform targeting junior doctors and students in India): Here, the new KDIGO guidelines for acute kidney injury AKI and the use of the biomarker, the NGAL test, are reviewed. This article is written by Dr. Deepak Marwah for junior doctors and medical students studying for exams. https://marwahmedicine.com/kdigo-2026-guidelines-2/Before KDIGO came out with their recommendations on the NGAL test, it was difficult to find scientific articles about the NGAL test. After the recommendations, they are popping up like pearls on a string. I have just found a new article from the scientific journal, Kidney Medicine, which describes a very large study where across 26 different studies of the NGAL test, they have compiled these results and concluded the following: That the kidney injury has often already happened at home. When acutely ill patients arrive at an emergency room/emergency department, their kidneys have often already sustained damage before they step through the door. The article shows that the NGAL test upon admission to the emergency room is already significantly elevated in those patients who are later diagnosed with acute kidney injury. They also emphasize that the old method should not stand alone, but must be used together with the NGAL test. It is a large international consortium of more than 25 leading nephrologists and intensivists from university hospitals in Europe, the USA, Asia, and Australia, led by German doctors Dr. Annemarie Albert and Dr. Christian Albert, who are the authors of this article https://www.sciencedirect.com/science/article/pii/S2590059526000415
- ·4.11.BioPorto – Presentation of Q3 2026 results 19.11.2026, at 13.00 https://www.inderes.dk/videos/bioporto-praesentation-af-q3-2026-resultaterI deleted the above post because I felt like it seemed as if I have inside information, I do not. I reacted to the fact that on October 28th, doubt was cast once again on whether it could be true when CB has repeatedly stated that he will find another option to cover this gap rather than a share issue, CB has replied several times that there are other options, such as loans and finding one or more partners, and selling the NGAL test, e.g. via license. I maintain that CB will find a partner. I believe this because with a stroke of a pen he will eliminate expenses of more than 20 million kroner per year. Those are the expenses Bioporto uses on selling the NGAL test, according to their financial reports. By getting a partnership agreement with a larger player, there will be several benefits for Bioporto Firstly, they will cover the gap of 20 million without incurring more expenses or shares on the market. Secondly, through their partner, Bioporto will get the NGAL test out to more hospitals at a greater speed than they can do themselves. Thirdly, Bioporto can keep full focus on getting the NGAL test for adults FDA approved. Fourthly, they can also keep full focus on further developing the test or entirely new products Since there are so many benefits for Bioporto in finding a partner, and that this solution does not create new challenges, I maintain that this is the solution we will hear more about at the next webcast. The above is not fact, it is my thoughts on what I believe will be the next step for Bioporto.
2.11.Julkaisu on poistettu.
·27.10.ASN Kidney week in Denver was just held from Oct 21-25. And here KDIGO was on the field with various presentations of their upcoming new guidelines. From ChatGPT follows the following: Guideline for Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD) • Status: The brand new updates were officially presented and reviewed during ASN Kidney Week in October 2026. • Expected release: The full, final guideline (KDIGO 2026 AKI/AKD Guideline) will be officially released at the end of 2026. Subclinical AKI and "Supra-clinical" biomarkers A major theme at the conference in relation to the new KDIGO 2026 guidelines was the concept of subclinical AKI. This covers a condition where a patient has normal creatinine (and thereby technically does not meet the old criteria for renal failure), but has sky-high NGAL levels. Studies show that these patients have just as poor prognoses and high mortality as those with visible renal failure, which is why NGAL is now integrated to catch these "blind spots" in the clinic. So maybe this is the year that BioPorto finally gives us the Christmas present that we have been waiting for in 15-20 years 🙏KDIGO has sent out this teaser for the aforementioned conference/fair to inform relevant physicians and specialists that new guidelines for acute kidney injury are coming. Marlies Ostermann (Co-Chair for KDIGO's working group) is leading the presentation of the new recommendations, which fundamentally change the way kidney injuries are diagnosed, paving the way for the implementation of new kidney tests like the NGAL test into the regular treatment routines of doctors https://myemail.constantcontact.com/KDIGO-Direct.html?soid=1134196072483&aid=bDgMCLLdDMg
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 45 616 | 45 616 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 45 616 | 45 616 | 0 | 0 |
2026 Q2 - tulosraportti
84 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 t sittenBIOPORTO (Q3) I 2026 regner Bioporto med at omsætte for 38-48 mio. kr. Det justerede driftsresultat før af- og nedskrivninger (EBITDA) ventes at udgøre et tab på 58-68 mio. kr.Dear 3D Why are you posting this? You aren't even posting it with a degree of understanding of what you are posting! BioPorto (Q3)... etc. When there is even something called Q3, it is because you have copied from the financial calendar.. As you have made yourself satisfied with what was published, it COULD be read as a kind of description OF Q3! However, it is not, and you have clipped it out of a calendar where Q3 is announced (Not WHAT is in the report, but THAT the report is coming on this and that day! So you are missing a date!!!! Besides, what you are posting is just 100% uninformative. I understand so little about you and am fed up to the back teeth with your unqualified messages! I think you should consider how insistent you are in your way of shoving yourself down over "a reality". Mvh. Bagerbrød
- ·4 t sitten · MuokattuMarwah Medicine (digital information platform targeting junior doctors and students in India): Here, the new KDIGO guidelines for acute kidney injury AKI and the use of the biomarker, the NGAL test, are reviewed. This article is written by Dr. Deepak Marwah for junior doctors and medical students studying for exams. https://marwahmedicine.com/kdigo-2026-guidelines-2/Before KDIGO came out with their recommendations on the NGAL test, it was difficult to find scientific articles about the NGAL test. After the recommendations, they are popping up like pearls on a string. I have just found a new article from the scientific journal, Kidney Medicine, which describes a very large study where across 26 different studies of the NGAL test, they have compiled these results and concluded the following: That the kidney injury has often already happened at home. When acutely ill patients arrive at an emergency room/emergency department, their kidneys have often already sustained damage before they step through the door. The article shows that the NGAL test upon admission to the emergency room is already significantly elevated in those patients who are later diagnosed with acute kidney injury. They also emphasize that the old method should not stand alone, but must be used together with the NGAL test. It is a large international consortium of more than 25 leading nephrologists and intensivists from university hospitals in Europe, the USA, Asia, and Australia, led by German doctors Dr. Annemarie Albert and Dr. Christian Albert, who are the authors of this article https://www.sciencedirect.com/science/article/pii/S2590059526000415
- ·4.11.BioPorto – Presentation of Q3 2026 results 19.11.2026, at 13.00 https://www.inderes.dk/videos/bioporto-praesentation-af-q3-2026-resultaterI deleted the above post because I felt like it seemed as if I have inside information, I do not. I reacted to the fact that on October 28th, doubt was cast once again on whether it could be true when CB has repeatedly stated that he will find another option to cover this gap rather than a share issue, CB has replied several times that there are other options, such as loans and finding one or more partners, and selling the NGAL test, e.g. via license. I maintain that CB will find a partner. I believe this because with a stroke of a pen he will eliminate expenses of more than 20 million kroner per year. Those are the expenses Bioporto uses on selling the NGAL test, according to their financial reports. By getting a partnership agreement with a larger player, there will be several benefits for Bioporto Firstly, they will cover the gap of 20 million without incurring more expenses or shares on the market. Secondly, through their partner, Bioporto will get the NGAL test out to more hospitals at a greater speed than they can do themselves. Thirdly, Bioporto can keep full focus on getting the NGAL test for adults FDA approved. Fourthly, they can also keep full focus on further developing the test or entirely new products Since there are so many benefits for Bioporto in finding a partner, and that this solution does not create new challenges, I maintain that this is the solution we will hear more about at the next webcast. The above is not fact, it is my thoughts on what I believe will be the next step for Bioporto.
- 2.11.Julkaisu on poistettu.
- ·27.10.ASN Kidney week in Denver was just held from Oct 21-25. And here KDIGO was on the field with various presentations of their upcoming new guidelines. From ChatGPT follows the following: Guideline for Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD) • Status: The brand new updates were officially presented and reviewed during ASN Kidney Week in October 2026. • Expected release: The full, final guideline (KDIGO 2026 AKI/AKD Guideline) will be officially released at the end of 2026. Subclinical AKI and "Supra-clinical" biomarkers A major theme at the conference in relation to the new KDIGO 2026 guidelines was the concept of subclinical AKI. This covers a condition where a patient has normal creatinine (and thereby technically does not meet the old criteria for renal failure), but has sky-high NGAL levels. Studies show that these patients have just as poor prognoses and high mortality as those with visible renal failure, which is why NGAL is now integrated to catch these "blind spots" in the clinic. So maybe this is the year that BioPorto finally gives us the Christmas present that we have been waiting for in 15-20 years 🙏KDIGO has sent out this teaser for the aforementioned conference/fair to inform relevant physicians and specialists that new guidelines for acute kidney injury are coming. Marlies Ostermann (Co-Chair for KDIGO's working group) is leading the presentation of the new recommendations, which fundamentally change the way kidney injuries are diagnosed, paving the way for the implementation of new kidney tests like the NGAL test into the regular treatment routines of doctors https://myemail.constantcontact.com/KDIGO-Direct.html?soid=1134196072483&aid=bDgMCLLdDMg
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 100 | ||
| 4 859 | ||
| 2 000 | ||
| 6 141 | ||
| 922 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. | 7 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 45 616 | 45 616 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 45 616 | 45 616 | 0 | 0 |
2026 Q2 - tulosraportti
84 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 19.11. | 7 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 21.5. | ||
2025 Q4 - tulosraportti 26.3. | ||
2025 Q3 - tulosraportti 19.11.2025 | ||
2025 Q2 - tulosraportti 15.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 t sittenBIOPORTO (Q3) I 2026 regner Bioporto med at omsætte for 38-48 mio. kr. Det justerede driftsresultat før af- og nedskrivninger (EBITDA) ventes at udgøre et tab på 58-68 mio. kr.Dear 3D Why are you posting this? You aren't even posting it with a degree of understanding of what you are posting! BioPorto (Q3)... etc. When there is even something called Q3, it is because you have copied from the financial calendar.. As you have made yourself satisfied with what was published, it COULD be read as a kind of description OF Q3! However, it is not, and you have clipped it out of a calendar where Q3 is announced (Not WHAT is in the report, but THAT the report is coming on this and that day! So you are missing a date!!!! Besides, what you are posting is just 100% uninformative. I understand so little about you and am fed up to the back teeth with your unqualified messages! I think you should consider how insistent you are in your way of shoving yourself down over "a reality". Mvh. Bagerbrød
- ·4 t sitten · MuokattuMarwah Medicine (digital information platform targeting junior doctors and students in India): Here, the new KDIGO guidelines for acute kidney injury AKI and the use of the biomarker, the NGAL test, are reviewed. This article is written by Dr. Deepak Marwah for junior doctors and medical students studying for exams. https://marwahmedicine.com/kdigo-2026-guidelines-2/Before KDIGO came out with their recommendations on the NGAL test, it was difficult to find scientific articles about the NGAL test. After the recommendations, they are popping up like pearls on a string. I have just found a new article from the scientific journal, Kidney Medicine, which describes a very large study where across 26 different studies of the NGAL test, they have compiled these results and concluded the following: That the kidney injury has often already happened at home. When acutely ill patients arrive at an emergency room/emergency department, their kidneys have often already sustained damage before they step through the door. The article shows that the NGAL test upon admission to the emergency room is already significantly elevated in those patients who are later diagnosed with acute kidney injury. They also emphasize that the old method should not stand alone, but must be used together with the NGAL test. It is a large international consortium of more than 25 leading nephrologists and intensivists from university hospitals in Europe, the USA, Asia, and Australia, led by German doctors Dr. Annemarie Albert and Dr. Christian Albert, who are the authors of this article https://www.sciencedirect.com/science/article/pii/S2590059526000415
- ·4.11.BioPorto – Presentation of Q3 2026 results 19.11.2026, at 13.00 https://www.inderes.dk/videos/bioporto-praesentation-af-q3-2026-resultaterI deleted the above post because I felt like it seemed as if I have inside information, I do not. I reacted to the fact that on October 28th, doubt was cast once again on whether it could be true when CB has repeatedly stated that he will find another option to cover this gap rather than a share issue, CB has replied several times that there are other options, such as loans and finding one or more partners, and selling the NGAL test, e.g. via license. I maintain that CB will find a partner. I believe this because with a stroke of a pen he will eliminate expenses of more than 20 million kroner per year. Those are the expenses Bioporto uses on selling the NGAL test, according to their financial reports. By getting a partnership agreement with a larger player, there will be several benefits for Bioporto Firstly, they will cover the gap of 20 million without incurring more expenses or shares on the market. Secondly, through their partner, Bioporto will get the NGAL test out to more hospitals at a greater speed than they can do themselves. Thirdly, Bioporto can keep full focus on getting the NGAL test for adults FDA approved. Fourthly, they can also keep full focus on further developing the test or entirely new products Since there are so many benefits for Bioporto in finding a partner, and that this solution does not create new challenges, I maintain that this is the solution we will hear more about at the next webcast. The above is not fact, it is my thoughts on what I believe will be the next step for Bioporto.
- 2.11.Julkaisu on poistettu.
- ·27.10.ASN Kidney week in Denver was just held from Oct 21-25. And here KDIGO was on the field with various presentations of their upcoming new guidelines. From ChatGPT follows the following: Guideline for Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD) • Status: The brand new updates were officially presented and reviewed during ASN Kidney Week in October 2026. • Expected release: The full, final guideline (KDIGO 2026 AKI/AKD Guideline) will be officially released at the end of 2026. Subclinical AKI and "Supra-clinical" biomarkers A major theme at the conference in relation to the new KDIGO 2026 guidelines was the concept of subclinical AKI. This covers a condition where a patient has normal creatinine (and thereby technically does not meet the old criteria for renal failure), but has sky-high NGAL levels. Studies show that these patients have just as poor prognoses and high mortality as those with visible renal failure, which is why NGAL is now integrated to catch these "blind spots" in the clinic. So maybe this is the year that BioPorto finally gives us the Christmas present that we have been waiting for in 15-20 years 🙏KDIGO has sent out this teaser for the aforementioned conference/fair to inform relevant physicians and specialists that new guidelines for acute kidney injury are coming. Marlies Ostermann (Co-Chair for KDIGO's working group) is leading the presentation of the new recommendations, which fundamentally change the way kidney injuries are diagnosed, paving the way for the implementation of new kidney tests like the NGAL test into the regular treatment routines of doctors https://myemail.constantcontact.com/KDIGO-Direct.html?soid=1134196072483&aid=bDgMCLLdDMg
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 100 | ||
| 4 859 | ||
| 2 000 | ||
| 6 141 | ||
| 922 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 45 616 | 45 616 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 45 616 | 45 616 | 0 | 0 |